Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:CAR T therapy in adult DLBCL patients in Slovenia : evaluation of predictive scores for outcomes and adverse events
Authors:ID Sršen, Lucija (Author)
ID Auersperger, Irena (Author)
ID Janžič, Larisa (Author)
ID Kopitar, Andreja Nataša (Author)
ID Reberšek, Katarina (Author)
ID Jezeršek Novaković, Barbara (Author)
ID Novak, Polona (Author)
ID Rener, Karla (Author)
ID Šlajpah, Klara (Author)
ID Ihan, Alojz (Author)
ID Zver, Samo (Author)
ID Sever, Matjaž (Author)
Files:.pdf PDF - Presentation file, download (6,40 MB)
MD5: 4C56CD2B9C3E090B355B49ABD11A56AC
 
URL URL - Source URL, visit https://www.tandfonline.com/doi/full/10.1080/21645515.2026.2620889
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo UKC LJ - Ljubljana University Medical Centre
Abstract:CAR T cell therapy is a promising immunotherapy for hematologic malignancies, yet early prediction of outcomes and adverse events remains difficult, especially in small real-world cohorts. We retrospectively analyzed 14 adult patients with diffuse large B-cell lymphoma (DLBCL) treated with CAR T cells in Slovenia, assessing IL-6 increase rates and established predictive metrics including EASIX-C, CAR-HEMATOTOX, and IBPS on Day -5 (pre-lymphodepletion) and Day 0 (infusion). Contrary to our expectation, an inverse correlation was observed between the increase rate of IL-6 and the occurrence of severe cytopenias, indicating higher IL-6 increase rate leads to less severe cytopenias. The EASIX-C score showed higher predictive values when calculated on Day 0, contrary to the CAR-HEMATOTOX score, whose higher predictive values were observed on Day -5. The IBPS predictive values showed mixed results when comparing Day -5 to Day 0. We observed 50% response rate and 29% remission rate. The results highlight the utility of predictive scores, with unexpected findings on IL-6 suggesting further study is necessary.
Keywords:CAR T cell therapy, adverse events, diffuse large B-cell lymphoma, hematologic malignancies
Publication status:Published
Publication version:Version of Record
Year of publishing:2026
Number of pages:str. 1-12
Numbering:Vol. 22, no. 1
PID:20.500.12556/DiRROS-28795 New window
UDC:616.1
ISSN on article:2164-5515
DOI:10.1080/21645515.2026.2620889 New window
COBISS.SI-ID:267251459 New window
Note:
Publication date in DiRROS:07.04.2026
Views:40
Downloads:17
Metadata:XML DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Human vaccines & immunotherapeutics
Shortened title:Hum. vaccin. immunother.
Publisher:Landes Bioscience
ISSN:2164-5515
COBISS.SI-ID:4534392 New window

Document is financed by a project

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P3-0083-2022
Name:Odnosi parazitskega obstajanja

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P3-0289-2019
Name:Značilnosti malignih neoplazem, pomembne za diagnozo ter napoved poteka bolezni in izida zdravljenja

Licences

License:CC BY-NC 4.0, Creative Commons Attribution-NonCommercial 4.0 International
Link:http://creativecommons.org/licenses/by-nc/4.0/
Description:A creative commons license that bans commercial use, but the users don’t have to license their derivative works on the same terms.

Secondary language

Language:Slovenian
Keywords:celično zdravljenje CAR T, neželeni učinki, difuzni velikocelični limfom, krvni raki


Back